Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.49 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20698336 | 0.88 | PDE3B (0.51) | PDE3BPDE3AALDH1A1MAOAMAOB | |
| SCHEMBL29036203 | 0.83 | PDE3B (0.57) | PDE3BPDE3AALDH1A1MAOAMAOB | |
| SCHEMBL30724416 | 0.82 | PDE3B (0.55) | PDE3BPDE3AALDH1A1MAOAMAOB | |
| SCHEMBL3350612 | 0.82 | PDE3B (0.55) | PDE3BPDE3AALDH1A1MAOAMAOB | |
| SCHEMBL5489309 | 0.78 | KDM4E (0.47) | TLK2KDM4ECDK1GSK3BCCNB2 | |
| SCHEMBL2849831 | 0.77 | PDE3B (0.53) | PDE3BPDE3AALDH1A1MAOAMAOB | |
| SCHEMBL31069587 | 0.77 | PDE3B (0.53) | PDE3BPDE3AALDH1A1MAOAMAOB | |
| SCHEMBL3639901 | 0.76 | TGM2 (0.42) | PDE3BPDE3AALDH1A1MAOAMAOB | |
| SCHEMBL1183750 | 0.76 | PDE3B (0.74) | PDE3BPDE3AALDH1A1MAOAMAOB | |
| SCHEMBL389879 | 0.76 | TGM2 (0.56) | LRRK2CDK2MAPTKDM4ECDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11142529-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210009602-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2021-01-14 | — | — | US | disclosed |
| US-10815242-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190284196-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2019-09-19 | — | — | US | disclosed |
| US-20190055258-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2019-02-21 | — | — | US | disclosed |
| US-20180170941-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2018-06-21 | — | — | US | disclosed |
| US-20170253603-A2 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| US-7687620-B2 | [1,4]diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents | WYETH LLC (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1497293-B1 | (1,4)DIAZEPINO(6,7,1-IJ)QUINOLINE DERIVATIVES AS ANTI PSYCHOTIC AND ANTIOBESITY AGENTS | WYETH CORP (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070004707-A1 | [1,4]Diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents | RAMAMOORTHY P S | 2007-01-04 | — | — | US | disclosed |
| US-7129237-B2 | [1,4]Diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | WYETH (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1497293-A1 | (1,4)DIAZEPINO(6,7,1-IJ)QUINOLINE DERIVATIVES AS ANTI PSYCHOTIC AND ANTIOBESITY AGENTS | Wyeth (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040009970-A1 | [1,4]Diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | WYETH | 2004-01-15 | — | — | US | disclosed |
| WO-2003091250-A1 | [1,4]DIAZEPINO[6,7,1-IJ]QUINOLINE DERIVATIVES AS ANTI PSYCHOTIC AND ANTIOBESITY AGENTS | WYETH (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004707-A1 | [1,4]Diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents | HTR2C, HTR1A, HTR1D | PDE3B 731/4885PDE3A 821/4885ALDH1A1 919/4885 |
| US-10815242-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | PDE3B 2978/4885PDE3A 2946/4885ALDH1A1 1862/4885 |
| US-20210009602-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | PDE3B 2978/4885PDE3A 2946/4885ALDH1A1 1862/4885 |
| US-20190055258-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | PDE3B 2978/4885PDE3A 2946/4885ALDH1A1 1862/4885 |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | PDE3B 2946/4885PDE3A 2945/4885ALDH1A1 1959/4885 |
| US-20190284196-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GRM1 | PDE3B 2990/4885PDE3A 2999/4885ALDH1A1 1823/4885 |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | PDE3B 2978/4885PDE3A 2946/4885ALDH1A1 1862/4885 |
| US-20040009970-A1 | [1,4]Diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | HTR2C, HTR1A, HTR1D | PDE3B 1139/4885PDE3A 1195/4885ALDH1A1 833/4885 |
| US-20180170941-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | PDE3B 2919/4885PDE3A 2914/4885ALDH1A1 1679/4885 |
| US-20170253603-A2 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | PDE3B 2978/4885PDE3A 2946/4885ALDH1A1 1862/4885 |
| US-11142529-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GRM1 | PDE3B 2990/4885PDE3A 2999/4885ALDH1A1 1823/4885 |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | PDE3B 2919/4885PDE3A 2914/4885ALDH1A1 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.